Skip to content

Source filing unavailable

Q1 2018 · —
Revenue$5.79M−61.0% vs Q1 2017+43.4% vs Q4 2017
Net Income-$12.05MN/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$25.76N/M vs Q1 2017N/M vs Q4 2017
Operating Income-$11,703,000—
Operating Cash Flow-$15,010,000—
Free Cash Flowderived-$15,374,000—
Margins · derived
Operating margin-202.0%
Net margin-207.9%−200.4 pt vs Q1 2017

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2018Q1 2017
Revenue$5.79M$14.85M
Net Income-$12.05M-$1.11M
EPS Diluted-$25.76-$2.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR